Subscribe
shutterstock_1427467406_art_studio_g
23 September 2021Jurisdiction reportsNaomi Pearce

Strategies for generic/biosimilar market entry in Australia

The pharma/biopharma industry shouldn’t underestimate the importance of strategising to achieve early market entry for generics and biosimilars, says Naomi Pearce of Pearce IP.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Patents
DABUS: decoding Australia’s AI decision
10 August 2021   Allowing an AI as an inventor could benefit the country’s pharma and drug discovery industries, say Richard Hamer, Lauren John and Alexandra Moloney of Allens.
Patents
Australia to safeguard tech IP by policing foreign R&D
11 March 2021   Australia has unveiled plans to expand the technologies in which international research and development collaboration will face increased scrutiny to protect the country’s IP.


Editor's picks

AI, lipstick deals and mental health: What’s on CITMA president’s radar?
Trademarks
AI, lipstick deals and mental health: What’s on CITMA president’s radar?
9 May 2025

Editor's picks

Trademarks
AI, lipstick deals and mental health: What’s on CITMA president’s radar?
9 May 2025
Patents
US-China tariffs: What hope is there for IP rightsholders?
1 May 2025
Trademarks
Thatchers, Skykick and dupes: What’s on a fashion IP influencer’s radar?
30 April 2025
Patents
Why US patent reform is ‘essential’ for US economic prosperity and security
28 April 2025
Patents
G1/23 ruling: Why a pending EPO decision threatens decade-old products
28 April 2025
Diversity
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
23 April 2025

More articles

UK-India trade deal is ‘missed opportunity’, say industry bodies
WATCH: Recent developments in design patent law
'Nothing can stand in the way of our work': Ukraine resumes IP system
Foley adds five-partner team from Perkins Coie and K&L Gates
WATCH: Finding a new balance in IP protection with trade secret protection
Optis v Apple: How the court calculated the royalty rate
Cahill expands practice with three-partner team from King & Spalding
Wouter Pors leaves Bird & Bird for boutique Dutch firm